Skip to content

Urinary Incontinence and Other Pelvic Floor Dysfunctions in Trail Runners

Urinary Incontinence and Other Pelvic Floor Dysfunctions in Trail Runners: Epidemiology and Identification of Risk Factors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06469320
Acronym
IU-TRAIL
Enrollment
1500
Registered
2024-06-21
Start date
2024-07-25
Completion date
2025-01-31
Last updated
2024-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Stress Incontinence

Brief summary

The pelvic floor is a crucial complex for many bodily functions, supporting the pelvic organs and contributing to urinary and anal continence, as well as sexual function. Dysfunction of this structure can lead to a variety of disorders, including urinary incontinence (UI), a common problem in women. Although the prevalence of UI in middle-aged women has been documented at between 20% and 30%, high-impact physical activities, such as certain sports and running, increase the risk of UI. According to the most recently published meta-analysis, the prevalence is 44% \[95%CI 30.2-57.8\]. Although this subject is often taboo, it can have psychosocial consequences and affect sporting activities. Only 31.7% of female runners talk to a health professional about it. Trail running, a fast-growing discipline, differs from road running in its particular physical demands, which could influence the occurrence of pelvic floor disorders (PFD) and exercise-induced UTIs. The unique characteristics of trail running, such as the technical nature of the terrain, the steep gradients and the variety of distances, place intense demands on the female pelvi-perineal system. Nevertheless, despite the growing popularity of this sport, little epidemiological data exists on the prevalence of stress UTI and pelvic floor disorders among female trail runners.

Interventions

OTHEROnline questionnaire

Pelvic floor dysfunction assessment questionnaire adapted from PFD-Sentinel

Sponsors

Centre Hospitalier Universitaire de la Réunion
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum

Inclusion criteria

* Adult runner * Residing in mainland France, or in French overseas departments and territories such as Guadeloupe, Martinique, French Guiana, Réunion, Mayotte and New Caledonia * Practising trail running on a regular basis (defined pragmatically by the participant herself), whether or not affiliated to a club * Able to complete the questionnaire online-

Exclusion criteria

* Pregnant or have given birth in the last six months * Does not understand French * A protected adult (guardianship or curatorship) or under court protection

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of stress urinary incontinence (SUI) and pelvic floor dysfunction (PFD)6 monthsThe prevalence will be determined by determining the proportion of female trail runners reporting Stress urinary incontinence and/or Pelvic floor muscle dysfunction out of the total population of trail runners who responded to the questionnaire.

Secondary

MeasureTime frameDescription
Identify the risk factors associated with SUI and PFD in French trail runners.6 monthsIdentification of the relative risks of the various suspected risk factors using a multiple logistic regression model
To assess the impact of SUI and PFD on the sporting activities and daily lives of French trail runners6 monthsThe various repercussions listed in the questionnaires will be presented in terms of the percentage of women affected and their 95% confidence interval. The averages of the visual analog scale associated with their parameters of dispersion in order to evaluate the impact of SUI on everyday life and in their sporting activities will also be presented.

Countries

Reunion

Contacts

Primary ContactNicolas Bouscaren, MD
nicolas.bouscaren@chu-reunion.fr+262 (0)2 62 35 90 00
Backup ContactLaetitia Berly, PhD
laetitia.berly@chu-reunion.fr+262 262906286

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026